Steven Grant, M.D. - Publications

Affiliations: 
Virginia Commonwealth University, Richmond, VA, United States 
Area:
Pharmacology, Biochemistry
Website:
https://medschool.vcu.edu/expertise/detail.html?ID=845

271 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Nguyen T, Parker R, Hawkins E, Holkova B, Yazbeck V, Kolluri A, Kmieciak M, Rahmani M, Grant S. Correction: Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur and and proceed through multiple mechanisms. Oncotarget. 10: 5383-5384. PMID 31523396 DOI: 10.18632/oncotarget.27175  0.6
2019 Booth L, Roberts JL, Cruickshanks N, Grant S, Poklepovic A, Dent P. Editor's Note: Regulation of OSU-03012 Toxicity by ER Stress Proteins and ER Stress-Inducing Drugs. Molecular Cancer Therapeutics. 18: 1669. PMID 31481480 DOI: 10.1158/1535-7163.MCT-19-0666  0.56
2019 Zhang Y, Zhou L, Bandyopadhyay D, Sharma K, Allen AJ, Kmieciak M, Grant S. The covalent CDK7 inhibitor THZ1 potently induces apoptosis in multiple myeloma cells in vitro and in vivo. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31358538 DOI: 10.1158/1078-0432.CCR-18-3788  0.6
2019 Dasmahapatra G, Patel H, Friedberg J, Quayle SN, Jones SS, Grant S. Retraction: and Interactions between the HDAC6 Inhibitor Ricolinostat (ACY1215) and the Irreversible Proteasome Inhibitor Carfilzomib in Non-Hodgkin Lymphoma Cells. Molecular Cancer Therapeutics. 18: 1181. PMID 31160511 DOI: 10.1158/1535-7163.MCT-19-0471  0.32
2019 Dasmahapatra G, Lembersky D, Son MP, Patel H, Peterson D, Attkisson E, Fisher RI, Friedberg JW, Dent P, Grant S. Retraction: Obatoclax Interacts Synergistically with the Irreversible Proteasome Inhibitor Carfilzomib in GC- and ABC-DLBCL Cells and . Molecular Cancer Therapeutics. 18: 1180. PMID 31160510 DOI: 10.1158/1535-7163.MCT-19-0470  0.56
2019 Dasmahapatra G, Lembersky D, Son MP, Attkisson E, Dent P, Fisher RI, Friedberg JW, Grant S. Retraction: Carfilzomib Interacts Synergistically with Histone Deacetylase Inhibitors in Mantle Cell Lymphoma Cells and . Molecular Cancer Therapeutics. 18: 1179. PMID 31160509 DOI: 10.1158/1535-7163.MCT-19-0469  0.56
2019 Han L, Zhang Q, Dail M, Shi C, Cavazos A, Ruvolo VR, Zhao Y, Kim E, Rahmani M, Mak DH, Jin SS, Chen J, Phillips DC, Bottecelli Koller P, Jacamo R, ... ... Grant S, et al. Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models. Haematologica. PMID 31123034 DOI: 10.3324/haematol.2018.205534  0.4
2019 Dasmahapatra G, Nguyen TK, Dent P, Grant S. Corrigendum to "Adaphostin and bortezomib induce oxidative injury and apoptosis in imatinib mesylate-resistant hematopoietic cells expressing mutant forms of Bcr/Abl" [Leuk. Res. 30 (2006) 1263-1272]. Leukemia Research. PMID 31079870 DOI: 10.1016/j.leukres.2019.03.002  0.56
2019 Zhou L, Zhang Y, Leng Y, Dai Y, Kmieciak M, Kramer L, Sharma K, Wang Y, Craun W, Grant S. The IAP antagonist birinapant potentiates bortezomib anti-myeloma activity in vitro and in vivo. Journal of Hematology & Oncology. 12: 25. PMID 30845975 DOI: 10.1186/s13045-019-0713-x  0.72
2018 Nguyen T, Parker R, Zhang Y, Hawkins E, Kmieciak M, Craun W, Grant S. Homoharringtonine interacts synergistically with bortezomib in NHL cells through MCL-1 and NOXA-dependent mechanisms. Bmc Cancer. 18: 1129. PMID 30445933 DOI: 10.1186/s12885-018-5018-x  0.6
2018 Yazbeck V, Shafer D, Perkins EB, Coppola D, Sokol L, Richards KL, Shea T, Ruan J, Parekh S, Strair R, Flowers C, Morgan D, Kmieciak M, Bose P, Kimball A, ... ... Grant S, et al. A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma. Clinical Lymphoma, Myeloma & Leukemia. 18: 569-575.e1. PMID 30122201 DOI: 10.1016/j.clml.2018.05.023  0.6
2018 Rahmani M, Nkwocha J, Hawkins E, Pei X, Parker RE, Kmieciak M, Leverson JD, Sampath D, Ferreira-Gonzalez A, Grant S. Co-targeting BCL-2 and PI3K induces BAX-dependent mitochondrial apoptosis in AML cells. Cancer Research. PMID 29559471 DOI: 10.1158/0008-5472.CAN-17-3024  0.6
2017 Zhou L, Zhang Y, Sampath D, Leverson J, Dai Y, Kmieciak M, Nguyen M, Orlowski RZ, Grant S. Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo. British Journal of Cancer. PMID 29241222 DOI: 10.1038/bjc.2017.432  0.72
2017 Zhang Y, Zhou L, Leng Y, Dai Y, Orlowski RZ, Grant S. Positive transcription elongation factor b (P-TEFb) is a therapeutic target in human multiple myeloma. Oncotarget. 8: 59476-59491. PMID 28938651 DOI: 10.18632/oncotarget.19761  0.72
2017 Nguyen T, Parker R, Hawkins E, Holkova B, Yazbeck V, Kolluri A, Kmieciak M, Rahmani M, Grant S. Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms. Oncotarget. PMID 28416758 DOI: 10.18632/oncotarget.15649  0.6
2017 Holkova B, Yazbeck V, Kmieciak M, Bose P, Ma S, Kimball A, Tombes MB, Shrader E, Wan W, Weir-Wiggins C, Singh A, Hogan KT, Conine S, Sankala H, Roberts JD, ... ... Grant S, et al. A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma. Leukemia & Lymphoma. 1-9. PMID 28103725 DOI: 10.1080/10428194.2016.1276287  0.6
2016 Turner JG, Kashyap T, Dawson JL, Gomez J, Bauer AA, Grant S, Dai Y, Shain KH, Meads M, Landesman Y, Sullivan DM. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma. Oncotarget. PMID 27806331 DOI: 10.18632/oncotarget.12969  0.72
2016 Zhang G, Park MA, Mitchell C, Walker T, Hamed H, Studer E, Graf M, Rahmani M, Gupta S, Hylemon PB, Fisher PB, Grant S, Dent P. Multiple cyclin kinase inhibitors promote bile acid-induced apoptosis and autophagy in primary hepatocytes via p53-CD95-dependent signaling. The Journal of Biological Chemistry. 291: 20823. PMID 27664064 DOI: 10.1074/jbc.A116.803444  0.56
2016 Turner JG, Dawson JL, Grant S, Shain KH, Dalton WS, Dai Y, Meads M, Baz R, Kauffman M, Shacham S, Sullivan DM. Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors. Journal of Hematology & Oncology. 9: 73. PMID 27557643 DOI: 10.1186/s13045-016-0304-z  0.72
2016 Rosato RR, Kolla SS, Hock SK, Almenara JA, Patel A, Amin S, Atadja P, Fisher PB, Dent P, Grant S. Histone deacetylase inhibitors activate NF-κB in human leukemia cells through an ATM/NEMO-related pathway. The Journal of Biological Chemistry. 291: 17535. PMID 27543593 DOI: 10.1074/jbc.A109.095208  0.56
2016 Wan W, Pei XY, Grant S, Birch JB, Felthousen J, Dai Y, Fang HB, Tan M, Sun S. Nonlinear response surface in the study of interaction analysis of three combination drugs. Biometrical Journal. Biometrische Zeitschrift. PMID 27185067 DOI: 10.1002/bimj.201500021  0.72
2016 Yu C, Dasmahapatra G, Dent P, Grant S. Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL+ human leukemia cells. Leukemia. PMID 27055874 DOI: 10.1038/leu.2016.7  0.56
2016 Zhou L, Chen S, Zhang Y, Kmieciak M, Leng Y, Li L, Lin H, Rizzo KA, Dumur CI, Ferreira-Gonzalez A, Rahmani M, Povirk L, Chalasani S, Berger AJ, Dai Y, ... Grant S, et al. The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR. Blood. PMID 26851293 DOI: 10.1182/blood-2015-06-653717  0.72
2016 Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo Arozena A, Adachi H, Adams CM, Adams PD, Adeli K, Adhihetty PJ, Adler SG, Agam G, Agarwal R, Aghi MK, ... ... Grant S, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 12: 1-222. PMID 26799652 DOI: 10.1080/15548627.2015.1100356  0.6
2015 Rahmani M, Aust MM, Hawkins E, Parker RE, Ross M, Kmieciak M, Reshko LB, Rizzo KA, Dumur CI, Ferreira-Gonzalez A, Grant S. Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation. Haematologica. PMID 26452980 DOI: 10.3324/haematol.2015.130351  0.72
2015 Holkova B, Zingone A, Kmieciak M, Bose P, Badros AZ, Voorhees PM, Baz R, Korde N, Lin HY, Chen JQ, Herrmann MA, Xi L, Raffeld M, Zhao X, Wan W, ... ... Grant S, et al. A Phase 2 Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26446942 DOI: 10.1158/1078-0432.CCR-15-1076  0.72
2015 Holkova B, Kmieciak M, Bose P, Yazbeck VY, Barr PM, Tombes MB, Shrader E, Weir-Wiggins C, Rollins AD, Cebula EM, Pierce E, Herr M, Sankala H, Hogan KT, Wan W, ... ... Grant S, et al. Phase 1 Trial of Carfilzomib (PR-171) in Combination with Vorinostat (SAHA) in Patients with Relapsed or Refractory B-Cell Lymphomas. Leukemia & Lymphoma. 1-30. PMID 26284612 DOI: 10.3109/10428194.2015.1075019  0.72
2015 Sperlazza J, Rahmani M, Beckta J, Aust M, Hawkins E, Wang SZ, Zhu SZ, Podder S, Dumur C, Archer K, Grant S, Ginder GD. Depletion of the chromatin remodeler CHD4 sensitizes AML blasts to genotoxic agents and reduces tumor formation. Blood. PMID 26265695 DOI: 10.1182/blood-2015-03-631606  0.44
2015 Grant S. ATRA and ATO team up against NPM1. Blood. 125: 3369-71. PMID 26022051 DOI: 10.1182/blood-2015-04-636217  0.72
2015 Yazbeck VY, Grant S. Romidepsin for the treatment of non-Hodgkin's lymphoma. Expert Opinion On Investigational Drugs. 24: 965-79. PMID 25936363 DOI: 10.1517/13543784.2015.1041586  0.72
2015 Fang HB, Chen X, Pei XY, Grant S, Tan M. Experimental design and statistical analysis for three-drug combination studies. Statistical Methods in Medical Research. PMID 25744107 DOI: 10.1177/0962280215574320  0.48
2015 Dai Y, Grant S. BCL2L11/Bim as a dual-agent regulating autophagy and apoptosis in drug resistance. Autophagy. 11: 416-8. PMID 25700997 DOI: 10.1080/15548627.2014.998892  0.72
2015 Nguyen T, Hawkins E, Kolluri A, Kmieciak M, Park H, Lin H, Grant S. Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR/ABL⁺ leukemia cells. Leukemia Research. 39: 65-71. PMID 25465126 DOI: 10.1016/j.leukres.2014.10.009  0.72
2015 Kiebala M, Skalska J, Casulo C, Brookes PS, Peterson DR, Hilchey SP, Dai Y, Grant S, Maggirwar SB, Bernstein SH. Dual targeting of the thioredoxin and glutathione antioxidant systems in malignant B cells: a novel synergistic therapeutic approach. Experimental Hematology. 43: 89-99. PMID 25448488 DOI: 10.1016/j.exphem.2014.10.004  0.72
2015 Zhou L, Zhang Y, Chen S, Kmieciak M, Leng Y, Lin H, Rizzo KA, Dumur CI, Ferreira-Gonzalez A, Dai Y, Grant S. A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations. Leukemia. 29: 807-18. PMID 25283841 DOI: 10.1038/leu.2014.296  0.72
2015 Hamed HA, Tavallai S, Grant S, Poklepovic A, Dent P. Sorafenib/regorafenib and lapatinib interact to kill CNS tumor cells. Journal of Cellular Physiology. 230: 131-9. PMID 24911215 DOI: 10.1002/jcp.24689  0.72
2015 Bose P, Grant S. Bcl-2 family: Translational aspects Targeted Therapy of Acute Myeloid Leukemi. 151-173. DOI: 10.1007/978-1-4939-1393-0_4  0.72
2014 Bose P, Batalo MS, Holkova B, Grant S. Bortezomib for the treatment of non-Hodgkin's lymphoma. Expert Opinion On Pharmacotherapy. 15: 2443-59. PMID 25263936 DOI: 10.1517/14656566.2014.965142  0.72
2014 Holkova B, Kmieciak M, Perkins EB, Bose P, Baz RC, Roodman GD, Stuart RK, Ramakrishnan V, Wan W, Peer CJ, Dawson J, Kang L, Honeycutt C, Tombes MB, Shrader E, ... ... Grant S, et al. Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 5652-62. PMID 25248382 DOI: 10.1158/1078-0432.CCR-14-0805  0.6
2014 Dasmahapatra G, Patel H, Friedberg J, Quayle SN, Jones SS, Grant S. In vitro and in vivo interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cells. Molecular Cancer Therapeutics. 13: 2886-97. PMID 25239935 DOI: 10.1158/1535-7163.MCT-14-0220  0.72
2014 Chen S, Zhang Y, Zhou L, Leng Y, Lin H, Kmieciak M, Pei XY, Jones R, Orlowski RZ, Dai Y, Grant S. A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis. Blood. 124: 2687-97. PMID 25208888 DOI: 10.1182/blood-2014-03-564534  0.72
2014 Gu D, Wang S, Kuiatse I, Wang H, He J, Dai Y, Jones RJ, Bjorklund CC, Yang J, Grant S, Orlowski RZ. Inhibition of the MDM2 E3 Ligase induces apoptosis and autophagy in wild-type and mutant p53 models of multiple myeloma, and acts synergistically with ABT-737. Plos One. 9: e103015. PMID 25181509 DOI: 10.1371/journal.pone.0103015  0.88
2014 Booth L, Roberts JL, Cruickshanks N, Grant S, Poklepovic A, Dent P. Regulation of OSU-03012 toxicity by ER stress proteins and ER stress-inducing drugs. Molecular Cancer Therapeutics. 13: 2384-98. PMID 25103559 DOI: 10.1158/1535-7163.MCT-14-0172  0.72
2014 Rahmani M, Aust MM, Benson EC, Wallace L, Friedberg J, Grant S. PI3K/mTOR inhibition markedly potentiates HDAC inhibitor activity in NHL cells through BIM- and MCL-1-dependent mechanisms in vitro and in vivo. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 4849-60. PMID 25070836 DOI: 10.1158/1078-0432.CCR-14-0034  0.72
2014 Chen S, Zhou L, Zhang Y, Leng Y, Pei XY, Lin H, Jones R, Orlowski RZ, Dai Y, Grant S. Targeting SQSTM1/p62 induces cargo loading failure and converts autophagy to apoptosis via NBK/Bik. Molecular and Cellular Biology. 34: 3435-49. PMID 25002530 DOI: 10.1128/MCB.01383-13  0.72
2014 Bose P, Grant S. Orphan drug designation for pracinostat, volasertib and alvocidib in AML. Leukemia Research. 38: 862-5. PMID 24996975 DOI: 10.1016/j.leukres.2014.06.007  0.72
2014 Vachhani P, Bose P, Rahmani M, Grant S. Rational combination of dual PI3K/mTOR blockade and Bcl-2/-xL inhibition in AML. Physiological Genomics. 46: 448-56. PMID 24824212 DOI: 10.1152/physiolgenomics.00173.2013  0.72
2014 Grant S. Bortezomib resistance and MUC1 in myeloma. Blood. 123: 2910-2. PMID 24810626 DOI: 10.1182/blood-2014-03-563882  0.72
2014 Cazanave SC, Wang X, Zhou H, Rahmani M, Grant S, Durrant DE, Klaassen CD, Yamamoto M, Sanyal AJ. Degradation of Keap1 activates BH3-only proteins Bim and PUMA during hepatocyte lipoapoptosis. Cell Death and Differentiation. 21: 1303-12. PMID 24769730 DOI: 10.1038/cdd.2014.49  0.72
2014 Bose P, Dai Y, Grant S. Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights. Pharmacology & Therapeutics. 143: 323-36. PMID 24769080 DOI: 10.1016/j.pharmthera.2014.04.004  0.72
2014 Xie JH, Yamniuk AP, Borowski V, Kuhn R, Susulic V, Rex-Rabe S, Yang X, Zhou X, Zhang Y, Gillooly K, Brosius R, Ravishankar R, Waggie K, Mink K, Price L, ... ... Grant S, et al. Engineering of a novel anti-CD40L domain antibody for treatment of autoimmune diseases. Journal of Immunology (Baltimore, Md. : 1950). 192: 4083-92. PMID 24670803 DOI: 10.4049/jimmunol.1303239  0.6
2014 Roberts JL, Booth L, Conley A, Cruickshanks N, Malkin M, Kukreja RC, Grant S, Poklepovic A, Dent P. PDE5 inhibitors enhance the lethality of standard of care chemotherapy in pediatric CNS tumor cells. Cancer Biology & Therapy. 15: 758-67. PMID 24651037 DOI: 10.4161/cbt.28553  0.72
2014 Pei XY, Dai Y, Felthousen J, Chen S, Takabatake Y, Zhou L, Youssefian LE, Sanderson MW, Bodie WW, Kramer LB, Orlowski RZ, Grant S. Circumvention of Mcl-1-dependent drug resistance by simultaneous Chk1 and MEK1/2 inhibition in human multiple myeloma cells. Plos One. 9: e89064. PMID 24594907 DOI: 10.1371/journal.pone.0089064  0.72
2014 Tavallai S, Hamed HA, Grant S, Poklepovic A, Dent P. Pazopanib and HDAC inhibitors interact to kill sarcoma cells. Cancer Biology & Therapy. 15: 578-85. PMID 24556916 DOI: 10.4161/cbt.28163  0.72
2014 Nguyen TK, Grant S. Dinaciclib (SCH727965) inhibits the unfolded protein response through a CDK1- and 5-dependent mechanism. Molecular Cancer Therapeutics. 13: 662-74. PMID 24362465 DOI: 10.1158/1535-7163.MCT-13-0714  0.72
2014 Booth L, Roberts JL, Cruickshanks N, Conley A, Durrant DE, Das A, Fisher PB, Kukreja RC, Grant S, Poklepovic A, Dent P. Phosphodiesterase 5 inhibitors enhance chemotherapy killing in gastrointestinal/genitourinary cancer cells. Molecular Pharmacology. 85: 408-19. PMID 24353313 DOI: 10.1124/mol.113.090043  0.72
2014 Booth L, Roberts JL, Conley A, Cruickshanks N, Ridder T, Grant S, Poklepovic A, Dent P. HDAC inhibitors enhance the lethality of low dose salinomycin in parental and stem-like GBM cells. Cancer Biology & Therapy. 15: 305-16. PMID 24351423 DOI: 10.4161/cbt.27309  0.72
2013 Hamed HA, Das SK, Sokhi UK, Park MA, Cruickshanks N, Archer K, Ogretmen B, Grant S, Sarkar D, Fisher PB, Dent P. Combining histone deacetylase inhibitors with MDA-7/IL-24 enhances killing of renal carcinoma cells. Cancer Biology & Therapy. 14: 1039-49. PMID 24025359 DOI: 10.4161/cbt.26110  0.72
2013 Cruickshanks N, Hamed HA, Booth L, Tavallai S, Syed J, Sajithlal GB, Grant S, Poklepovic A, Dent P. Histone deacetylase inhibitors restore toxic BH3 domain protein expression in anoikis-resistant mammary and brain cancer stem cells, thereby enhancing the response to anti-ERBB1/ERBB2 therapy. Cancer Biology & Therapy. 14: 982-96. PMID 24025251 DOI: 10.4161/cbt.26234  0.72
2013 Bose P, Park H, Al-Khafaji J, Grant S. Strategies to circumvent the T315I gatekeeper mutation in the Bcr-Abl tyrosine kinase. Leukemia Research Reports. 2: 18-20. PMID 23977454 DOI: 10.1016/j.lrr.2013.02.001  0.72
2013 Bose P, Grant S. Mcl-1 as a Therapeutic Target in Acute Myelogenous Leukemia (AML). Leukemia Research Reports. 2: 12-14. PMID 23977453 DOI: 10.1016/j.lrr.2012.11.006  0.72
2013 Booth L, Cruickshanks N, Ridder T, Dai Y, Grant S, Dent P. PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells. Cancer Biology & Therapy. 14: 458-65. PMID 23917378 DOI: 10.4161/cbt.24424  0.72
2013 Sajithlal GB, Hamed HA, Cruickshanks N, Booth L, Tavallai S, Syed J, Grant S, Poklepovic A, Dent P. Sorafenib/regorafenib and phosphatidyl inositol 3 kinase/thymoma viral proto-oncogene inhibition interact to kill tumor cells. Molecular Pharmacology. 84: 562-71. PMID 23877009 DOI: 10.1124/mol.113.088005  0.72
2013 Liu K, Zhang D, Chojnacki J, Du Y, Fu H, Grant S, Zhang S. Design and biological characterization of hybrid compounds of curcumin and thalidomide for multiple myeloma. Organic & Biomolecular Chemistry. 11: 4757-63. PMID 23784627 DOI: 10.1039/c3ob40595h  0.44
2013 Hamed HA, Yamaguchi Y, Fisher PB, Grant S, Dent P. Sorafenib and HDAC inhibitors synergize with TRAIL to kill tumor cells. Journal of Cellular Physiology. 228: 1996-2005. PMID 23674352 DOI: 10.1002/jcp.24362  0.72
2013 Hamed HA, Yacoub A, Park MA, Archer K, Das SK, Sarkar D, Grant S, Fisher PB, Dent P. Histone deacetylase inhibitors interact with melanoma differentiation associated-7/interleukin-24 to kill primary human glioblastoma cells. Molecular Pharmacology. 84: 171-81. PMID 23661648 DOI: 10.1124/mol.113.086553  0.72
2013 Bose P, Simmons GL, Grant S. Cyclin-dependent kinase inhibitor therapy for hematologic malignancies. Expert Opinion On Investigational Drugs. 22: 723-38. PMID 23647051 DOI: 10.1517/13543784.2013.789859  0.72
2013 Dai Y, Chen S, Kmieciak M, Zhou L, Lin H, Pei XY, Grant S. The novel Chk1 inhibitor MK-8776 sensitizes human leukemia cells to HDAC inhibitors by targeting the intra-S checkpoint and DNA replication and repair. Molecular Cancer Therapeutics. 12: 878-89. PMID 23536721 DOI: 10.1158/1535-7163.MCT-12-0902  0.72
2013 Holkova B, Supko JG, Ames MM, Reid JM, Shapiro GI, Perkins EB, Ramakrishnan V, Tombes MB, Honeycutt C, McGovern RM, Kmieciak M, Shrader E, Wellons MD, Sankala H, Doyle A, ... ... Grant S, et al. A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 1873-83. PMID 23515411 DOI: 10.1158/1078-0432.CCR-12-2926  0.72
2013 Liu K, Guo TL, Hait NC, Allegood J, Parikh HI, Xu W, Kellogg GE, Grant S, Spiegel S, Zhang S. Biological characterization of 3-(2-amino-ethyl)-5-[3-(4-butoxyl-phenyl)-propylidene]-thiazolidine-2,4-dione (K145) as a selective sphingosine kinase-2 inhibitor and anticancer agent. Plos One. 8: e56471. PMID 23437140 DOI: 10.1371/journal.pone.0056471  0.72
2013 Dasmahapatra G, Patel H, Dent P, Fisher RI, Friedberg J, Grant S. The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib. British Journal of Haematology. 161: 43-56. PMID 23360303 DOI: 10.1111/bjh.12206  0.56
2013 Rahmani M, Aust MM, Attkisson E, Williams DC, Ferreira-Gonzalez A, Grant S. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism. Cancer Research. 73: 1340-51. PMID 23243017 DOI: 10.1158/0008-5472.CAN-12-1365  0.72
2013 Das SK, Bhutia SK, Azab B, Kegelman TP, Peachy L, Santhekadur PK, Dasgupta S, Dash R, Dent P, Grant S, Emdad L, Pellecchia M, Sarkar D, Fisher PB. MDA-9/syntenin and IGFBP-2 promote angiogenesis in human melanoma. Cancer Research. 73: 844-54. PMID 23233738 DOI: 10.1158/0008-5472.CAN-12-1681  0.56
2013 Dasmahapatra G, Patel H, Nguyen T, Attkisson E, Grant S. PLK1 inhibitors synergistically potentiate HDAC inhibitor lethality in imatinib mesylate-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 404-14. PMID 23204129 DOI: 10.1158/1078-0432.CCR-12-2799  0.44
2012 Bose P, Rahmani M, Grant S. Coordinate PI3K pathway and Bcl-2 family disruption in AML. Oncotarget. 3: 1499-500. PMID 23439314  0.72
2012 Bose P, Grant S. Complementary combinations: what treatments will become key to the battle against acute myelogenous leukemia? Expert Review of Hematology. 5: 475-8. PMID 23146050 DOI: 10.1586/ehm.12.43  0.72
2012 Harrison SJ, Bishton M, Bates SE, Grant S, Piekarz RL, Johnstone RW, Dai Y, Lee B, Araujo ME, Prince HM. A focus on the preclinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax(®)). Epigenomics. 4: 571-89. PMID 23130838 DOI: 10.2217/epi.12.52  0.72
2012 Grant S, Dai Y. Histone deacetylase inhibitors and rational combination therapies. Advances in Cancer Research. 116: 199-237. PMID 23088872 DOI: 10.1016/B978-0-12-394387-3.00006-9  0.72
2012 Booth L, Cruickshanks N, Ridder T, Chen CS, Grant S, Dent P. OSU-03012 interacts with lapatinib to kill brain cancer cells. Cancer Biology & Therapy. 13: 1501-11. PMID 22990204 DOI: 10.4161/cbt.22275  0.56
2012 Cruickshanks N, Tang Y, Booth L, Hamed H, Grant S, Dent P. Lapatinib and obatoclax kill breast cancer cells through reactive oxygen species-dependent endoplasmic reticulum stress. Molecular Pharmacology. 82: 1217-29. PMID 22989520 DOI: 10.1124/mol.112.081539  0.56
2012 Yaseen A, Chen S, Hock S, Rosato R, Dent P, Dai Y, Grant S. Resveratrol sensitizes acute myelogenous leukemia cells to histone deacetylase inhibitors through reactive oxygen species-mediated activation of the extrinsic apoptotic pathway. Molecular Pharmacology. 82: 1030-41. PMID 22923501 DOI: 10.1124/mol.112.079624  0.72
2012 Chen S, Dai Y, Pei XY, Myers J, Wang L, Kramer LB, Garnett M, Schwartz DM, Su F, Simmons GL, Richey JD, Larsen DG, Dent P, Orlowski RZ, Grant S. CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies. Cancer Research. 72: 4225-37. PMID 22693249 DOI: 10.1158/0008-5472.CAN-12-1118  0.72
2012 Bareford MD, Hamed HA, Allegood J, Cruickshanks N, Poklepovic A, Park MA, Ogretmen B, Spiegel S, Grant S, Dent P. Sorafenib and pemetrexed toxicity in cancer cells is mediated via SRC-ERK signaling. Cancer Biology & Therapy. 13: 793-803. PMID 22673740 DOI: 10.4161/cbt.20562  0.72
2012 Tang Y, Hamed HA, Poklepovic A, Dai Y, Grant S, Dent P. Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in mammary tumors. Molecular Pharmacology. 82: 322-32. PMID 22596349 DOI: 10.1124/mol.112.078907  0.72
2012 Rahmani M, Aust MM, Attkisson E, Williams DC, Ferreira-Gonzalez A, Grant S. Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process. Blood. 119: 6089-98. PMID 22446485 DOI: 10.1182/blood-2011-09-378141  0.72
2012 Dasmahapatra G, Lembersky D, Son MP, Patel H, Peterson D, Attkisson E, Fisher RI, Friedberg JW, Dent P, Grant S. Obatoclax interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC- and ABC-DLBCL cells in vitro and in vivo. Molecular Cancer Therapeutics. 11: 1122-32. PMID 22411899 DOI: 10.1158/1535-7163.MCT-12-0021  0.56
2012 Tang Y, Yacoub A, Hamed HA, Poklepovic A, Tye G, Grant S, Dent P. Sorafenib and HDAC inhibitors synergize to kill CNS tumor cells. Cancer Biology & Therapy. 13: 567-74. PMID 22406992 DOI: 10.4161/cbt.19771  0.72
2012 Cruickshanks N, Hamed HA, Bareford MD, Poklepovic A, Fisher PB, Grant S, Dent P. Lapatinib and obatoclax kill tumor cells through blockade of ERBB1/3/4 and through inhibition of BCL-XL and MCL-1. Molecular Pharmacology. 81: 748-58. PMID 22357666 DOI: 10.1124/mol.112.077586  0.72
2012 Booth L, Cazanave SC, Hamed HA, Yacoub A, Ogretmen B, Chen CS, Grant S, Dent P. OSU-03012 suppresses GRP78/BiP expression that causes PERK-dependent increases in tumor cell killing. Cancer Biology & Therapy. 13: 224-36. PMID 22354011 DOI: 10.4161/cbt.13.4.18877  0.72
2012 Tang Y, Dai Y, Grant S, Dent P. Enhancing CHK1 inhibitor lethality in glioblastoma. Cancer Biology & Therapy. 13: 379-88. PMID 22313687 DOI: 10.4161/cbt.19240  0.72
2012 Tang Y, Hamed HA, Cruickshanks N, Fisher PB, Grant S, Dent P. Obatoclax and lapatinib interact to induce toxic autophagy through NOXA. Molecular Pharmacology. 81: 527-40. PMID 22219388 DOI: 10.1124/mol.111.076851  0.72
2012 Liu K, Rao W, Parikh H, Li Q, Guo TL, Grant S, Kellogg GE, Zhang S. 3,5-Disubstituted-thiazolidine-2,4-dione analogs as anticancer agents: design, synthesis and biological characterization. European Journal of Medicinal Chemistry. 47: 125-37. PMID 22074985 DOI: 10.1016/j.ejmech.2011.10.031  0.72
2012 Rosato R, Hock S, Dent P, Dai Y, Grant S. LBH-589 (panobinostat) potentiates fludarabine anti-leukemic activity through a JNK- and XIAP-dependent mechanism. Leukemia Research. 36: 491-8. PMID 22074700 DOI: 10.1016/j.leukres.2011.10.020  0.72
2012 Azab B, Dash R, Das SK, Bhutia SK, Shen XN, Quinn BA, Sarkar S, Wang XY, Hedvat M, Dmitriev IP, Curiel DT, Grant S, Dent P, Reed JC, Pellecchia M, et al. Enhanced delivery of mda-7/IL-24 using a serotype chimeric adenovirus (Ad.5/3) in combination with the Apogossypol derivative BI-97C1 (Sabutoclax) improves therapeutic efficacy in low CAR colorectal cancer cells. Journal of Cellular Physiology. 227: 2145-53. PMID 21780116 DOI: 10.1002/jcp.22947  0.72
2012 Bhutia SK, Das SK, Kegelman TP, Azab B, Dash R, Su ZZ, Wang XY, Rizzi F, Bettuzzi S, Lee SG, Dent P, Grant S, Curiel DT, Sarkar D, Fisher PB. mda-7/IL-24 differentially regulates soluble and nuclear clusterin in prostate cancer. Journal of Cellular Physiology. 227: 1805-13. PMID 21732348 DOI: 10.1002/jcp.22904  0.72
2012 Spiegel S, Milstien S, Grant S. Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy. Oncogene. 31: 537-51. PMID 21725353 DOI: 10.1038/onc.2011.267  0.72
2011 Pei XY, Dai Y, Youssefian LE, Chen S, Bodie WW, Takabatake Y, Felthousen J, Almenara JA, Kramer LB, Dent P, Grant S. Cytokinetically quiescent (G0/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2. Blood. 118: 5189-200. PMID 21911831 DOI: 10.1182/blood-2011-02-339432  0.72
2011 Dai Y, Grant S. Methods to study cancer therapeutic drugs that target cell cycle checkpoints. Methods in Molecular Biology (Clifton, N.J.). 782: 257-304. PMID 21870298 DOI: 10.1007/978-1-61779-273-1_19  0.72
2011 Zhang Q, Sturgill JL, Kmieciak M, Szczepanek K, Derecka M, Koebel C, Graham LJ, Dai Y, Chen S, Grant S, Cichy J, Shimoda K, Gamero A, Manjili M, Bear H, et al. The role of Tyk2 in regulation of breast cancer growth. Journal of Interferon & Cytokine Research : the Official Journal of the International Society For Interferon and Cytokine Research. 31: 671-7. PMID 21864028 DOI: 10.1089/jir.2011.0023  0.72
2011 Quinn BA, Dash R, Azab B, Sarkar S, Das SK, Kumar S, Oyesanya RA, Dasgupta S, Dent P, Grant S, Rahmani M, Curiel DT, Dmitriev I, Hedvat M, Wei J, et al. Targeting Mcl-1 for the therapy of cancer. Expert Opinion On Investigational Drugs. 20: 1397-411. PMID 21851287 DOI: 10.1517/13543784.2011.609167  0.72
2011 Dai Y, Chen S, Wang L, Pei XY, Funk VL, Kramer LB, Dent P, Grant S. Disruption of IkappaB kinase (IKK)-mediated RelA serine 536 phosphorylation sensitizes human multiple myeloma cells to histone deacetylase (HDAC) inhibitors. The Journal of Biological Chemistry. 286: 34036-50. PMID 21816815 DOI: 10.1074/jbc.M111.284216  0.72
2011 Bareford MD, Hamed HA, Tang Y, Cruickshanks N, Burow ME, Fisher PB, Moran RG, Nephew KP, Grant S, Dent P. Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells. Autophagy. 7: 1261-2. PMID 21814046 DOI: 10.4161/auto.7.10.17029  0.72
2011 Dasmahapatra G, Lembersky D, Son MP, Attkisson E, Dent P, Fisher RI, Friedberg JW, Grant S. Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo. Molecular Cancer Therapeutics. 10: 1686-97. PMID 21750224 DOI: 10.1158/1535-7163.MCT-10-1108  0.56
2011 Mitchell C, Hamed HA, Cruickshanks N, Tang Y, Bareford MD, Hubbard N, Tye G, Yacoub A, Dai Y, Grant S, Dent P. Simultaneous exposure of transformed cells to SRC family inhibitors and CHK1 inhibitors causes cell death. Cancer Biology & Therapy. 12: 215-28. PMID 21642769 DOI: 10.4161/cbt.12.3.16218  0.72
2011 Bareford MD, Park MA, Yacoub A, Hamed HA, Tang Y, Cruickshanks N, Eulitt P, Hubbard N, Tye G, Burow ME, Fisher PB, Moran RG, Nephew KP, Grant S, Dent P. Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells. Cancer Research. 71: 4955-67. PMID 21622715 DOI: 10.1158/0008-5472.CAN-11-0898  0.72
2011 Dash R, Azab B, Quinn BA, Shen X, Wang XY, Das SK, Rahmani M, Wei J, Hedvat M, Dent P, Dmitriev IP, Curiel DT, Grant S, Wu B, Stebbins JL, et al. Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24-mediated toxicity. Proceedings of the National Academy of Sciences of the United States of America. 108: 8785-90. PMID 21555592 DOI: 10.1073/pnas.1100769108  0.72
2011 Dent P, Tang Y, Yacoub A, Dai Y, Fisher PB, Grant S. CHK1 inhibitors in combination chemotherapy: thinking beyond the cell cycle. Molecular Interventions. 11: 133-40. PMID 21540473 DOI: 10.1124/mi.11.2.11  0.72
2011 Nguyen T, Dai Y, Attkisson E, Kramer L, Jordan N, Nguyen N, Kolluri N, Muschen M, Grant S. HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 3219-32. PMID 21474579 DOI: 10.1158/1078-0432.CCR-11-0234  0.72
2011 Holkova B, Perkins EB, Ramakrishnan V, Tombes MB, Shrader E, Talreja N, Wellons MD, Hogan KT, Roodman GD, Coppola D, Kang L, Dawson J, Stuart RK, Peer C, Figg WD, ... ... Grant S, et al. Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 3388-97. PMID 21447728 DOI: 10.1158/1078-0432.CCR-10-2876  0.72
2011 Dai Y, Chen S, Wang L, Pei XY, Kramer LB, Dent P, Grant S. Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF-κB and Bim. British Journal of Haematology. 153: 222-35. PMID 21375523 DOI: 10.1111/j.1365-2141.2011.08591.x  0.72
2011 Dash R, Azab B, Shen XN, Sokhi UK, Sarkar S, Su ZZ, Wang XY, Claudio PP, Dent P, Dmitriev IP, Curiel DT, Grant S, Sarkar D, Fisher PB. Developing an effective gene therapy for prostate cancer: New technologies with potential to translate from the laboratory into the clinic. Discovery Medicine. 11: 46-56. PMID 21276410  0.72
2011 Friedberg JW, Vose JM, Kelly JL, Young F, Bernstein SH, Peterson D, Rich L, Blumel S, Proia NK, Liesveld J, Fisher RI, Armitage JO, Grant S, Leonard JP. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood. 117: 2807-12. PMID 21239695 DOI: 10.1182/blood-2010-11-314708  0.72
2011 Dai Y, Chen S, Shah R, Pei XY, Wang L, Almenara JA, Kramer LB, Dent P, Grant S. Disruption of Src function potentiates Chk1-inhibitor-induced apoptosis in human multiple myeloma cells in vitro and in vivo. Blood. 117: 1947-57. PMID 21148814 DOI: 10.1182/blood-2010-06-291146  0.72
2011 Park MA, Hamed HA, Mitchell C, Cruickshanks N, Dash R, Allegood J, Dmitriev IP, Tye G, Ogretmen B, Spiegel S, Yacoub A, Grant S, Curiel DT, Fisher PB, Dent P. A serotype 5/3 adenovirus expressing MDA-7/IL-24 infects renal carcinoma cells and promotes toxicity of agents that increase ROS and ceramide levels. Molecular Pharmacology. 79: 368-80. PMID 21119025 DOI: 10.1124/mol.110.069484  0.72
2011 Dickson MA, Rathkopf DE, Carvajal RD, Grant S, Roberts JD, Reid JM, Ames MM, McGovern RM, Lefkowitz RA, Gonen M, Cane LM, Dials HJ, Schwartz GK. A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors. Investigational New Drugs. 29: 1004-12. PMID 20461440 DOI: 10.1007/s10637-010-9447-x  0.72
2010 Dash R, Bhutia SK, Azab B, Su ZZ, Quinn BA, Kegelmen TP, Das SK, Kim K, Lee SG, Park MA, Yacoub A, Rahmani M, Emdad L, Dmitriev IP, Wang XY, ... ... Grant S, et al. mda-7/IL-24: a unique member of the IL-10 gene family promoting cancer-targeted toxicity. Cytokine & Growth Factor Reviews. 21: 381-91. PMID 20926331 DOI: 10.1016/j.cytogfr.2010.08.004  0.72
2010 Rahmani M, Mayo M, Dash R, Sokhi UK, Dmitriev IP, Sarkar D, Dent P, Curiel DT, Fisher PB, Grant S. Melanoma differentiation associated gene-7/interleukin-24 potently induces apoptosis in human myeloid leukemia cells through a process regulated by endoplasmic reticulum stress. Molecular Pharmacology. 78: 1096-104. PMID 20858700 DOI: 10.1124/mol.110.068007  0.72
2010 Dai Y, Guzman ML, Chen S, Wang L, Yeung SK, Pei XY, Dent P, Jordan CT, Grant S. The NF (Nuclear factor)-κB inhibitor parthenolide interacts with histone deacetylase inhibitors to induce MKK7/JNK1-dependent apoptosis in human acute myeloid leukaemia cells. British Journal of Haematology. 151: 70-83. PMID 20701602 DOI: 10.1111/j.1365-2141.2010.08319.x  0.72
2010 Zimmerman EI, Dollins CM, Crawford M, Grant S, Nana-Sinkam SP, Richards KL, Hammond SM, Graves LM. Lyn kinase-dependent regulation of miR181 and myeloid cell leukemia-1 expression: implications for drug resistance in myelogenous leukemia. Molecular Pharmacology. 78: 811-7. PMID 20693279 DOI: 10.1124/mol.110.066258  0.72
2010 Park MA, Reinehr R, Häussinger D, Voelkel-Johnson C, Ogretmen B, Yacoub A, Grant S, Dent P. Sorafenib activates CD95 and promotes autophagy and cell death via Src family kinases in gastrointestinal tumor cells. Molecular Cancer Therapeutics. 9: 2220-31. PMID 20682655 DOI: 10.1158/1535-7163.MCT-10-0274  0.72
2010 Li Q, Wu J, Zheng H, Liu K, Guo TL, Liu Y, Eblen ST, Grant S, Zhang S. Discovery of 3-(2-aminoethyl)-5-(3-phenyl-propylidene)-thiazolidine-2,4-dione as a dual inhibitor of the Raf/MEK/ERK and the PI3K/Akt signaling pathways. Bioorganic & Medicinal Chemistry Letters. 20: 4526-30. PMID 20580230 DOI: 10.1016/j.bmcl.2010.06.030  0.44
2010 Walker T, Mitchell C, Park MA, Yacoub A, Rahmani M, Häussinger D, Reinehr R, Voelkel-Johnson C, Fisher PB, Grant S, Dent P. 17-allylamino-17-demethoxygeldanamycin and MEK1/2 inhibitors kill GI tumor cells via Ca2+-dependent suppression of GRP78/BiP and induction of ceramide and reactive oxygen species. Molecular Cancer Therapeutics. 9: 1378-95. PMID 20442308 DOI: 10.1158/1535-7163.MCT-09-1131  0.56
2010 Bhutia SK, Dash R, Das SK, Azab B, Su ZZ, Lee SG, Grant S, Yacoub A, Dent P, Curiel DT, Sarkar D, Fisher PB. Mechanism of autophagy to apoptosis switch triggered in prostate cancer cells by antitumor cytokine melanoma differentiation-associated gene 7/interleukin-24. Cancer Research. 70: 3667-76. PMID 20406981 DOI: 10.1158/0008-5472.CAN-09-3647  0.72
2010 Hamed HA, Yacoub A, Park MA, Eulitt PJ, Dash R, Sarkar D, Dmitriev IP, Lesniak MS, Shah K, Grant S, Curiel DT, Fisher PB, Dent P. Inhibition of multiple protective signaling pathways and Ad.5/3 delivery enhances mda-7/IL-24 therapy of malignant glioma. Molecular Therapy : the Journal of the American Society of Gene Therapy. 18: 1130-42. PMID 20179672 DOI: 10.1038/mt.2010.29  0.72
2010 Nguyen TK, Jordan N, Friedberg J, Fisher RI, Dent P, Grant S. Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis. Leukemia Research. 34: 379-86. PMID 20117835 DOI: 10.1016/j.leukres.2009.07.013  0.56
2010 Hamed HA, Yacoub A, Park MA, Eulitt P, Sarkar D, Dimitrie IP, Chen CS, Grant S, Curiel DT, Fisher PB, Dent P. OSU-03012 enhances Ad.7-induced GBM cell killing via ER stress and autophagy and by decreasing expression of mitochondrial protective proteins. Cancer Biology & Therapy. 9: 526-36. PMID 20107314  0.72
2010 Yacoub A, Hamed HA, Allegood J, Mitchell C, Spiegel S, Lesniak MS, Ogretmen B, Dash R, Sarkar D, Broaddus WC, Grant S, Curiel DT, Fisher PB, Dent P. PERK-dependent regulation of ceramide synthase 6 and thioredoxin play a key role in mda-7/IL-24-induced killing of primary human glioblastoma multiforme cells. Cancer Research. 70: 1120-9. PMID 20103619 DOI: 10.1158/0008-5472.CAN-09-4043  0.72
2010 Rosato RR, Kolla SS, Hock SK, Almenara JA, Patel A, Amin S, Atadja P, Fisher PB, Dent P, Grant S. Histone deacetylase inhibitors activate NF-kappaB in human leukemia cells through an ATM/NEMO-related pathway. The Journal of Biological Chemistry. 285: 10064-77. PMID 20065354 DOI: 10.1074/jbc.M109.095208  0.56
2010 Yacoub A, Liu R, Park MA, Hamed HA, Dash R, Schramm DN, Sarkar D, Dimitriev IP, Bell JK, Grant S, Farrell NP, Curiel DT, Fisher PB, Dent P. Cisplatin enhances protein kinase R-like endoplasmic reticulum kinase- and CD95-dependent melanoma differentiation-associated gene-7/interleukin-24-induced killing in ovarian carcinoma cells. Molecular Pharmacology. 77: 298-310. PMID 19910452 DOI: 10.1124/mol.109.061820  0.72
2009 Dent P, Curiel DT, Grant S, Fisher PB. Minting a new class of polo-like-kinase inhibitors. Cancer Biology & Therapy. 8: 2384-5. PMID 20009506  0.72
2009 Martin AP, Mitchell C, Rahmani M, Nephew KP, Grant S, Dent P. Inhibition of MCL-1 enhances lapatinib toxicity and overcomes lapatinib resistance via BAK-dependent autophagy. Cancer Biology & Therapy. 8: 2084-96. PMID 19823038 DOI: 10.4161/cbt.8.21.9895  0.56
2009 Li Q, Al-Ayoubi A, Guo T, Zheng H, Sarkar A, Nguyen T, Eblen ST, Grant S, Kellogg GE, Zhang S. Structure-activity relationship (SAR) studies of 3-(2-amino-ethyl)-5-(4-ethoxy-benzylidene)-thiazolidine-2,4-dione: development of potential substrate-specific ERK1/2 inhibitors. Bioorganic & Medicinal Chemistry Letters. 19: 6042-6. PMID 19796943 DOI: 10.1016/j.bmcl.2009.09.057  0.44
2009 Martin AP, Park MA, Mitchell C, Walker T, Rahmani M, Thorburn A, Häussinger D, Reinehr R, Grant S, Dent P. BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing. Molecular Pharmacology. 76: 327-41. PMID 19483105 DOI: 10.1124/mol.109.056309  0.56
2009 Park MA, Walker T, Martin AP, Allegood J, Vozhilla N, Emdad L, Sarkar D, Rahmani M, Graf M, Yacoub A, Koumenis C, Spiegel S, Curiel DT, Voelkel-Johnson C, Grant S, et al. MDA-7/IL-24-induced cell killing in malignant renal carcinoma cells occurs by a ceramide/CD95/PERK-dependent mechanism. Molecular Cancer Therapeutics. 8: 1280-91. PMID 19417161 DOI: 10.1158/1535-7163.MCT-09-0073  0.72
2009 Emdad L, Lebedeva IV, Su ZZ, Gupta P, Sauane M, Dash R, Grant S, Dent P, Curiel DT, Sarkar D, Fisher PB. Historical perspective and recent insights into our understanding of the molecular and biochemical basis of the antitumor properties of mda-7/IL-24. Cancer Biology & Therapy. 8: 391-400. PMID 19276652  0.72
2009 Dasmahapatra G, Lembersky D, Rahmani M, Kramer L, Friedberg J, Fisher RI, Dent P, Grant S. Bcl-2 antagonists interact synergistically with bortezomib in DLBCL cells in association with JNK activation and induction of ER stress. Cancer Biology & Therapy. 8: 808-19. PMID 19270531 DOI: 10.4161/cbt.8.9.8131  0.6
2009 Dent P, Grant S, Fisher PB, Curiel DT. PI3K: A rational target for ovarian cancer therapy? Cancer Biology & Therapy. 8: 27-30. PMID 19127116  0.72
2008 Rosato RR, Almenara JA, Maggio SC, Coe S, Atadja P, Dent P, Grant S. Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions Molecular Cancer Therapeutics. 7: 3285-3297. PMID 18852132 DOI: 10.1158/1535-7163.MCT-08-0385  0.72
2008 Park MA, Zhang G, Mitchell C, Rahmani M, Hamed H, Hagan MP, Yacoub A, Curiel DT, Fisher PB, Grant S, Dent P. Mitogen-activated protein kinase kinase 1/2 inhibitors and 17-allylamino-17-demethoxygeldanamycin synergize to kill human gastrointestinal tumor cells in vitro via suppression of c-FLIP-s levels and activation of CD95. Molecular Cancer Therapeutics. 7: 2633-48. PMID 18790746 DOI: 10.1158/1535-7163.MCT-08-0400  0.72
2008 Park MA, Zhang G, Martin AP, Hamed H, Mitchell C, Hylemon PB, Graf M, Rahmani M, Ryan K, Liu X, Spiegel S, Norris J, Fisher PB, Grant S, Dent P. Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation. Cancer Biology & Therapy. 7: 1648-62. PMID 18787411 DOI: 10.4161/cbt.7.10.6623  0.72
2008 Zhang G, Park MA, Mitchell C, Hamed H, Rahmani M, Martin AP, Curiel DT, Yacoub A, Graf M, Lee R, Roberts JD, Fisher PB, Grant S, Dent P. Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 5385-99. PMID 18765530 DOI: 10.1158/1078-0432.CCR-08-0469  0.72
2008 Park MA, Zhang G, Norris J, Hylemon PB, Fisher PB, Grant S, Dent P. Regulation of autophagy by ceramide-CD95-PERK signaling Autophagy. 4: 929-931. PMID 18719356 DOI: 10.4161/auto.6732  0.72
2008 Dent P, Yacoub A, Park M, Sarkar D, Shah K, Curiel DT, Grant S, Fisher PB. Searching for a cure: gene therapy for glioblastoma. Cancer Biology & Therapy. 7: 1335-40. PMID 18708757  0.72
2008 Zhang G, Park MA, Mitchell C, Walker T, Hamed H, Studer E, Graf M, Rahmani M, Gupta S, Hylemon PB, Fisher PB, Grant S, Dent P. Multiple cyclin kinase inhibitors promote bile acid-induced apoptosis and autophagy in primary hepatocytes via p53-CD95-dependent signaling. The Journal of Biological Chemistry. 283: 24343-58. PMID 18614532 DOI: 10.1074/jbc.M803444200  0.72
2008 Martin AP, Miller A, Emad L, Rahmani M, Walker T, Mitchell C, Hagan MP, Park MA, Yacoub A, Fisher PB, Grant S, Dent P. Lapatinib resistance in HCT116 cells is mediated by elevated MCL-1 expression and decreased BAK activation and not by ERBB receptor kinase mutation. Molecular Pharmacology. 74: 807-22. PMID 18544666 DOI: 10.1124/mol.108.047365  0.56
2008 Paugh SW, Paugh BS, Rahmani M, Kapitonov D, Almenara JA, Kordula T, Milstien S, Adams JK, Zipkin RE, Grant S, Spiegel S. A selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemia. Blood. 112: 1382-91. PMID 18511810 DOI: 10.1182/blood-2008-02-138958  0.72
2008 Hamed H, Mitchell C, Park MA, Hanna D, Martin AP, Harrison B, Hawkins W, Curiel DA, Fisher PB, Grant S, Yacoub A, Hagan MP, Dent P. Human chorionic gonadotropin (hCG) interacts with lovastatin and ionizing radiation to modulate prostate cancer cell viability in vivo. Cancer Biology & Therapy. 7: 587-93. PMID 18379195 DOI: 10.4161/cbt.7.4.5543  0.56
2008 Yacoub A, Hamed H, Emdad L, Dos Santos W, Gupta P, Broaddus WC, Ramakrishnan V, Sarkar D, Shah K, Curiel DT, Grant S, Fisher PB, Dent P. MDA-7/IL-24 plus radiation enhance survival in animals with intracranial primary human GBM tumors. Cancer Biology & Therapy. 7: 917-33. PMID 18376144 DOI: 10.4161/cbt.7.6.5928  0.72
2008 Hamed H, Hawkins W, Mitchell C, Gilfor D, Zhang G, Pei XY, Dai Y, Hagan MP, Roberts JD, Yacoub A, Grant S, Dent P. Transient exposure of carcinoma cells to RAS/MEK inhibitors and UCN-01 causes cell death in vitro and in vivo. Molecular Cancer Therapeutics. 7: 616-29. PMID 18347148 DOI: 10.1158/1535-7163.MCT-07-2376  0.72
2008 Park MA, Yacoub A, Sarkar D, Emdad L, Rahmani M, Spiegel S, Koumenis C, Graf M, Curiel DT, Grant S, Fisher PB, Dent P. PERK-dependent regulation of MDA-7/IL-24-induced autophagy in primary human glioma cells. Autophagy. 4: 513-5. PMID 18299661  0.72
2008 Yacoub A, Gupta P, Park MA, Rhamani M, Hamed H, Hanna D, Zhang G, Sarkar D, Lebedeva IV, Emdad L, Koumenis C, Curiel DT, Grant S, Fisher PB, Dent P. Regulation of GST-MDA-7 toxicity in human glioblastoma cells by ERBB1, ERK1/2, PI3K, and JNK1-3 pathway signaling Molecular Cancer Therapeutics. 7: 314-329. PMID 18281516 DOI: 10.1158/1535-7163.MCT-07-2150  0.72
2008 Yacoub A, Park MA, Gupta P, Rahmani M, Zhang G, Hamed H, Hanna D, Sarkar D, Lebedeva IV, Emdad L, Sauane M, Vozhilla N, Spiegel S, Koumenis C, Graf M, ... ... Grant S, et al. Caspase-, cathepsin-, and PERK-dependent regulation of MDA-7/IL-24-induced cell killing in primary human glioma cells. Molecular Cancer Therapeutics. 7: 297-313. PMID 18281515 DOI: 10.1158/1535-7163.MCT-07-2166  0.72
2008 Dai Y, Chen S, Kramer LB, Funk VL, Dent P, Grant S. Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 549-58. PMID 18223231 DOI: 10.1158/1078-0432.CCR-07-1934  0.72
2008 Park MA, Curiel DT, Koumenis C, Graf M, Chen CS, Fisher PB, Grant S, Dent P. PERK-dependent regulation of HSP70 expression and the regulation of autophagy. Autophagy. 4: 364-7. PMID 18216498  0.72
2008 Park MA, Yacoub A, Rahmani M, Zhang G, Hart L, Hagan MP, Calderwood SK, Sherman MY, Koumenis C, Spiegel S, Chen CS, Graf M, Curiel DT, Fisher PB, Grant S, et al. OSU-03012 stimulates PKR-like endoplasmic reticulum-dependent increases in 70-kDa heat shock protein expression, attenuating its lethal actions in transformed cells. Molecular Pharmacology. 73: 1168-84. PMID 18182481 DOI: 10.1124/mol.107.042697  0.72
2008 Grant S. Cotargeting survival signaling pathways in cancer (Journal of Clinical Investigation (2008) 118, (3003-3006) DOI: 10.1172/JCI36898) Journal of Clinical Investigation. 118: 3513. DOI: 10.1172/JCI36898E1  0.72
2007 Dent P, Hylemon PB, Grant S, Fisher PB. Approaches for monitoring signal transduction changes in normal and cancer cells Methods in Molecular Biology (Clifton, N.J.). 383: 259-276. PMID 18217691 DOI: 10.1007/978-1-59745-335-6_17  0.72
2007 Mitchell C, Park MA, Zhang G, Yacoub A, Curiel DT, Fisher PB, Roberts JD, Grant S, Dent P. Extrinsic pathway- and cathepsin-dependent induction of mitochondrial dysfunction are essential for synergistic flavopiridol and vorinostat lethality in breast cancer cells. Molecular Cancer Therapeutics. 6: 3101-12. PMID 18065490 DOI: 10.1158/1535-7163.MCT-07-0561  0.72
2007 Lebedeva IV, Emdad L, Su ZZ, Gupta P, Sauane M, Sarkar D, Staudt MR, Liu SJ, Taher MM, Xiao R, Barral P, Lee SG, Wang D, Vozhilla N, Park ES, ... ... Grant S, et al. mda-7/IL-24, novel anticancer cytokine: focus on bystander antitumor, radiosensitization and antiangiogenic properties and overview of the phase I clinical experience (Review). International Journal of Oncology. 31: 985-1007. PMID 17912425  0.72
2007 Dasmahapatra G, Yerram N, Dai Y, Dent P, Grant S. Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and p21CIP1 down-regulation Clinical Cancer Research. 13: 4280-4290. PMID 17634558 DOI: 10.1158/1078-0432.CCR-07-0835  0.72
2007 Rahmani M, Nguyen TK, Dent P, Grant S. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation. Molecular Pharmacology. 72: 788-95. PMID 17595328 DOI: 10.1124/mol.106.033308  0.72
2007 Grant S, Dent P. Simultaneous interruption of signal transduction and cell cycle regulatory pathways: Implications for new approaches to the treatment of childhood leukemias Current Drug Targets. 8: 751-759. PMID 17584030 DOI: 10.2174/138945007780830764  0.72
2007 Mitchell C, Kabolizadeh P, Ryan J, Roberts JD, Yacoub A, Curiel DT, Fisher PB, Hagan MP, Farrell NP, Grant S, Dent P. Low-dose BBR3610 toxicity in colon cancer cells is p53-independent and enhanced by inhibition of epidermal growth factor receptor (ERBB1)-phosphatidyl inositol 3 kinase signaling. Molecular Pharmacology. 72: 704-14. PMID 17578896 DOI: 10.1124/mol.107.038406  0.72
2007 Rahmani M, Davis EM, Crabtree TR, Habibi JR, Nguyen TK, Dent P, Grant S. The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress. Molecular and Cellular Biology. 27: 5499-513. PMID 17548474 DOI: 10.1128/MCB.01080-06  0.56
2007 Valerie K, Yacoub A, Hagan MP, Curiel DT, Fisher PB, Grant S, Dent P. Radiation-induced cell signaling: inside-out and outside-in. Molecular Cancer Therapeutics. 6: 789-801. PMID 17363476 DOI: 10.1158/1535-7163.MCT-06-0596  0.72
2007 Rosato RR, Almenara JA, Kolla SS, Maggio SC, Coe S, Giménez MS, Dent P, Grant S. Mechanism and functional role of XIAP and Mcl-1 down-regulation in flavopiridol/vorinostat antileukemic interactions Molecular Cancer Therapeutics. 6: 692-702. PMID 17308065 DOI: 10.1158/1535-7163.MCT-06-0562  0.72
2007 Mitchell C, Park MA, Zhang G, Han SI, Harada H, Franklin RA, Yacoub A, Li PL, Hylemon PB, Grant S, Dent P. 17-Allylamino-17-demethoxygeldanamycin enhances the lethality of deoxycholic acid in primary rodent hepatocytes and established cell lines. Molecular Cancer Therapeutics. 6: 618-32. PMID 17308059 DOI: 10.1158/1535-7163.MCT-06-0532  0.72
2007 Dai Y, Khanna P, Chen S, Pei XY, Dent P, Grant S. Statins synergistically potentiate 7-hydroxystaurosporine (UCN-01) lethality in human leukemia and myeloma cells by disrupting Ras farnesylation and activation. Blood. 109: 4415-23. PMID 17264303 DOI: 10.1182/blood-2006-09-047076  0.72
2007 Nguyen TK, Rahmani M, Harada H, Dent P, Grant S. MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825. Blood. 109: 4006-15. PMID 17218385 DOI: 10.1182/blood-2006-09-045039  0.72
2007 Fisher PB, Sarkar D, Lebedeva IV, Emdad L, Gupta P, Sauane M, Su ZZ, Grant S, Dent P, Curiel DT, Senzer N, Nemunaitis J. Melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24): novel gene therapeutic for metastatic melanoma. Toxicology and Applied Pharmacology. 224: 300-7. PMID 17208263 DOI: 10.1016/j.taap.2006.11.021  0.72
2007 Fang Y, Studer E, Mitchell C, Grant S, Pandak WM, Hylemon PB, Dent P. Conjugated bile acids regulate hepatocyte glycogen synthase activity in vitro and in vivo via Galphai signaling. Molecular Pharmacology. 71: 1122-8. PMID 17200418 DOI: 10.1124/mol.106.032060  0.72
2007 Yacoub A, Hawkins W, Hanna D, Young H, Park MA, Grant M, Roberts JD, Curiel DT, Fisher PB, Valerie K, Grant S, Hagan MP, Dent P. Human chorionic gonadotropin modulates prostate cancer cell survival after irradiation or HMG CoA reductase inhibitor treatment. Molecular Pharmacology. 71: 259-75. PMID 17050804 DOI: 10.1124/mol.106.031153  0.72
2006 Yacoub A, Miller A, Caron RW, Qiao L, Curiel DA, Fisher PB, Hagan MP, Grant S, Dent P. Radiotherapy-induced signal transduction. Endocrine-Related Cancer. 13: S99-114. PMID 17259563 DOI: 10.1677/erc.1.01271  0.56
2006 Roberts JD, Smith MR, Feldman EJ, Cragg L, Millenson MM, Roboz GJ, Honeycutt C, Thune R, Padavic-Shaller K, Carter WH, Ramakrishnan V, Murgo AJ, Grant S. Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 5809-16. PMID 17020988 DOI: 10.1158/1078-0432.CCR-05-2730  0.72
2006 Yacoub A, Gilfor D, Hawkins W, Park MA, Hanna D, Hagan MP, Curiel DT, Fisher PB, Grant S, Dent P. MEK1/2 inhibition promotes Taxotere lethality in mammary tumors in vivo. Cancer Biology & Therapy. 5: 1332-9. PMID 16957420 DOI: 10.4161/cbt.5.10.3215  0.56
2006 Yacoub A, Park MA, Hanna D, Hong Y, Mitchell C, Pandya AP, Harada H, Powis G, Chen CS, Koumenis C, Grant S, Dent P. OSU-03012 promotes caspase-independent but PERK-, cathepsin B-, BID-, and AIF-dependent killing of transformed cells. Molecular Pharmacology. 70: 589-603. PMID 16622074 DOI: 10.1124/mol.106.025007  0.56
2006 Nguyen TK, Rahmani M, Gao N, Kramer L, Corbin AS, Druker BJ, Dent P, Grant S. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 2239-47. PMID 16609040 DOI: 10.1158/1078-0432.CCR-05-2282  0.6
2006 Dasmahapatra G, Nguyen TK, Dent P, Grant S. Adaphostin and bortezomib induce oxidative injury and apoptosis in imatinib mesylate-resistant hematopoietic cells expressing mutant forms of Bcr/Abl. Leukemia Research. 30: 1263-72. PMID 16481037 DOI: 10.1016/j.leukres.2006.01.005  0.72
2006 Dai Y, Hamm TE, Dent P, Grant S. Cyclin D1 overexpression increases the susceptibility of human U266 myeloma cells to CDK inhibitors through a process involving p130-, p107- and E2F-dependent S phase entry Cell Cycle. 5: 437-446. PMID 16479154 DOI: 10.4161/cc.5.4.2441  0.72
2006 Gupta P, Su ZZ, Lebedeva IV, Sarkar D, Sauane M, Emdad L, Bachelor MA, Grant S, Curiel DT, Dent P, Fisher PB. mda-7/IL-24: multifunctional cancer-specific apoptosis-inducing cytokine. Pharmacology & Therapeutics. 111: 596-628. PMID 16464504 DOI: 10.1016/j.pharmthera.2005.11.005  0.56
2006 Rosato RR, Maggio SC, Almenara JA, Payne SG, Atadja P, Spiegel S, Dent P, Grant S. The histone deacetylase inhibitor LAQ824 induces human leukemia cell death through a process involving XIAP down-regulation, oxidative injury, and the acid sphingomyelinase-dependent generation of ceramide. Molecular Pharmacology. 69: 216-25. PMID 16189296 DOI: 10.1124/mol.105.017145  0.72
2006 Dasmahapatra G, Rahmani M, Dent P, Grant S. The tyrphostin adaphostin interacts synergistically with proteasome inhibitors to induce apoptosis in human leukemia cells through a reactive oxygen species (ROS)-dependent mechanism Blood. 107: 232-240. PMID 16166589 DOI: 10.1182/blood-2005-06-2302  0.72
2005 Hawkins W, Mitchell C, McKinstry R, Gilfor D, Starkey J, Dai Y, Dawson K, Ramakrishnan V, Roberts JD, Yacoub A, Grant S, Dent P. Transient exposure of mammary tumors to PD184352 and UCN-01 causes tumor cell death in vivo and prolonged suppression of tumor regrowth. Cancer Biology & Therapy. 4: 1275-84. PMID 16319524 DOI: 10.4161/cbt.4.11.2286  0.72
2005 Rosato RR, Almenara JA, Maggio SC, Atadja P, Craig R, Vrana J, Dent P, Grant S. Potentiation of the lethality of the histone deacetylase inhibitor LAQ824 by the cyclin-dependent kinase inhibitor roscovitine in human leukemia cells Molecular Cancer Therapeutics. 4: 1772-1785. PMID 16275999 DOI: 10.1158/1535-7163.MCT-05-0157  0.72
2005 Dent P, Han SI, Mitchell C, Studer E, Yacoub A, Grandis J, Grant S, Krystal GW, Hylemon PB. Inhibition of insulin/IGF-1 receptor signaling enhances bile acid toxicity in primary hepatocytes. Biochemical Pharmacology. 70: 1685-96. PMID 16207485 DOI: 10.1016/j.bcp.2005.08.020  0.72
2005 Rahmani M, Davis EM, Bauer C, Dent P, Grant S. Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation Journal of Biological Chemistry. 280: 35217-35227. PMID 16109713 DOI: 10.1074/jbc.M506551200  0.72
2005 Yu C, Dasmahapatra G, Dent P, Grant S. Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL+ human leukemia cells Leukemia. 19: 1579-1589. PMID 16015388 DOI: 10.1038/sj.leu.2403868  0.72
2005 Dent P, Yacoub A, Grant S. DMC: Novel celecoxib derivatives to rap cancer Cancer Biology and Therapy. 4: 583-584. PMID 15970676 DOI: 10.4161/cbt.4.5.1794  0.72
2005 Dai Y, Rahmani M, Dent P, Grant S. Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-κB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation Molecular and Cellular Biology. 25: 5429-5444. PMID 15964800 DOI: 10.1128/MCB.25.13.5429-5444.2005  0.72
2005 Dent P, Yacoub A, Grant S, Curiel DT, Fisher PB. MDA-7/IL-24 regulates proliferation, invasion and tumor cell radiosensitivity: A new cancer therapy? Journal of Cellular Biochemistry. 95: 712-719. PMID 15880678 DOI: 10.1002/jcb.20502  0.72
2005 Gao N, Rahmani M, Dent P, Grant S. 2-Methoxyestradiol-induced apoptosis in human leukemia cells proceeds through a reactive oxygen species and Akt-dependent process Oncogene. 24: 3797-3809. PMID 15782127 DOI: 10.1038/sj.onc.1208530  0.72
2005 Rahmani M, Reese E, Dai Y, Bauer C, Payne SG, Dent P, Spiegel S, Grant S. Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species. Cancer Research. 65: 2422-32. PMID 15781658 DOI: 10.1158/0008-5472.CAN-04-2440  0.72
2005 Carón RW, Yacoub A, Mitchell C, Zhu X, Hong Y, Sasazuki T, Shirasawa S, Hagan MP, Grant S, Dent P. Radiation-stimulated ERK1/2 and JNK1/2 signaling can promote cell cycle progression in human colon cancer cells. Cell Cycle (Georgetown, Tex.). 4: 456-64. PMID 15655348 DOI: 10.4161/cc.4.3.1249  0.56
2005 Dai Y, Rahmani M, Pei XY, Khanna P, Han SI, Mitchell C, Dent P, Grant S. Farnesyltransferase inhibitors interact synergistically with the Chk1 inhibitor UCN-01 to induce apoptosis in human leukemia cells through interruption of both Akt and MEK/ERK pathways and activation of SEK1/JNK. Blood. 105: 1706-16. PMID 15494423 DOI: 10.1182/blood-2004-07-2767  0.72
2004 Dent P, Grant S. Irofulven: Resurgence for alkylating therapy in cancer? Cancer Biology and Therapy. 3: 1143-1144. PMID 15640616 DOI: 10.4161/cbt.3.11.1306  0.72
2004 Ahmed W, Rahmani M, Dent P, Grant S. The cyclin-dependent kinase inhibitor p21CIP1/WAF1 blocks paclitaxel-induced G2M arrest and attenuates mitochondrial injury and apoptosis in p53-null human leukemia cells Cell Cycle. 3: 1305-1311. PMID 15467449 DOI: 10.4161/cc.3.10.1161  0.72
2004 Rosato RR, Dai Y, Almenara JA, Maggio SC, Grant ST. Potent antileukemia interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation Leukemia. 18: 1780-1788. PMID 15385934 DOI: 10.1038/sj.leu.2403491  0.72
2004 Yacoub A, Mitchell C, Hong Y, Gopalkrishnan RV, Su ZZ, Gupta P, Sauane M, Lebedeva IV, Curiel DT, Mahasreshti PJ, Rosenfeld MR, Broaddus WC, James CD, Grant S, Fisher PB, et al. MDA-7 regulates cell growth and radiosensitivity in vitro of primary (non-established) human glioma cells. Cancer Biology & Therapy. 3: 739-51. PMID 15197348  0.72
2004 Dai Y, Rahmani M, Corey SJ, Dent P, Grant S. A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. The Journal of Biological Chemistry. 279: 34227-39. PMID 15175350 DOI: 10.1074/jbc.M402290200  0.72
2004 Pei XY, Dai Y, Grant S. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 3839-52. PMID 15173093 DOI: 10.1158/1078-0432.CCR-03-0561  0.52
2004 Grant S, Dent P. Activation of MAP kinase pathways by TRAIL: Don't expect the obvious Cancer Biology and Therapy. 3: 302-304. PMID 15107606 DOI: 10.4161/cbt.3.3.749  0.72
2004 Yu C, Rahmani M, Dent P, Grant S. The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor Bortezomib Experimental Cell Research. 295: 555-566. PMID 15093752 DOI: 10.1016/j.yexcr.2004.02.001  0.72
2004 Grant S, Dent P. Kinase Inhibitors and Cytotoxic Drug Resistance Clinical Cancer Research. 10: 2205-2207. PMID 15073093 DOI: 10.1158/1078-0432.CCR-0001-4  0.72
2004 Maggio SC, Rosato RR, Kramer LB, Dai Y, Rahmani M, Paik DS, Czarnik AC, Payne SG, Spiegel S, Grant S. The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells. Cancer Research. 64: 2590-600. PMID 15059916 DOI: 10.1158/0008-5472.CAN-03-2631  0.72
2004 Han SI, Studer E, Gupta S, Fang Y, Qiao L, Li W, Grant S, Hylemon PB, Dent P. Bile Acids Enhance the Activity of the Insulin Receptor and Glycogen Synthase in Primary Rodent Hepatocytes Hepatology. 39: 456-463. PMID 14767998 DOI: 10.1002/hep.20043  0.72
2004 Dai Y, Pei XY, Rahmani M, Conrad DH, Dent P, Grant S. Interruption of the NF-kappaB pathway by Bay 11-7082 promotes UCN-01-mediated mitochondrial dysfunction and apoptosis in human multiple myeloma cells. Blood. 103: 2761-70. PMID 14645003 DOI: 10.1182/blood-2003-09-3037  0.72
2003 Dai Y, Dent P, Grant S. Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Promotes Mitochondrial Dysfunction and Apoptosis Induced by 7-Hydroxystaurosporine and Mitogen-Activated Protein Kinase Kinase Inhibitors in Human Leukemia Cells That Ectopically Express Bcl-2 and Bcl-xL Molecular Pharmacology. 64: 1402-1409. PMID 14645670 DOI: 10.1124/mol.64.6.1402  0.72
2003 Yu C, Subler M, Rahmani M, Reese E, Krystal G, Conrad D, Dent P, Grant S. Induction of apoptosis in BCR/ABL+ cells by histone deacetylase inhibitors involves reciprocal effects on the RAF/MEK/ERK and JNK pathways. Cancer Biology & Therapy. 2: 544-51. PMID 14614324 DOI: 10.4161/cbt.2.5.454  0.72
2003 Dai Y, Rahmani M, Grant S. Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-κB-dependent process Oncogene. 22: 7108-7122. PMID 14562039 DOI: 10.1038/sj.onc.1206863  0.72
2003 Pei XY, Dai Y, Grant S. The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells. Leukemia. 17: 2036-45. PMID 14513055 DOI: 10.1038/sj.leu.2403109  0.36
2003 Yacoub A, Mitchell C, Lebedeva IV, Sarkar D, Su ZZ, McKinstry R, Gopalkrishnan RV, Grant S, Fisher PB, Dent P. mda-7 (IL-24) Inhibits growth and enhances radiosensitivity of glioma cells in vitro via JNK signaling. Cancer Biology & Therapy. 2: 347-53. PMID 14508103 DOI: 10.4161/cbt.2.4.422  0.56
2003 Rahmani M, Yu C, Reese E, Ahmed W, Hirsch K, Dent P, Grant S. Inhibition of PI-3 kinase sensitizes human leukemic cells to histone deacetylase inhibitor-mediated apoptosis through p44/42 MAP kinase inactivation and abrogation of p21(CIP1/WAF1) induction rather than AKT inhibition. Oncogene. 22: 6231-42. PMID 13679862 DOI: 10.1038/sj.onc.1206646  0.56
2003 Dent P, Yacoub A, Fisher PB, Hagan MP, Grant S. MAPK pathways in radiation responses. Oncogene. 22: 5885-96. PMID 12947395 DOI: 10.1038/sj.onc.1206701  0.72
2003 Yu C, Rahmani M, Conrad D, Subler M, Dent P, Grant S. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. Blood. 102: 3765-74. PMID 12893773 DOI: 10.1182/blood-2003-03-0737  0.72
2003 Decker RH, Levin J, Kramer LB, Dai Y, Grant S. Enforced expression of the tumor suppressor p53 renders human leukemia cells (U937) more sensitive to 1-[beta-D-arabinofuranosyl]cytosine (ara-C)-induced apoptosis. Biochemical Pharmacology. 65: 1997-2008. PMID 12787880 DOI: 10.1016/S0006-2952(03)00149-7  0.72
2003 Qiao L, Han SI, Fang Y, Park JS, Gupta S, Gilfor D, Amorino G, Valerie K, Sealy L, Engelhardt JF, Grant S, Hylemon PB, Dent P. Bile acid regulation of C/EBPbeta, CREB, and c-Jun function, via the extracellular signal-regulated kinase and c-Jun NH2-terminal kinase pathways, modulates the apoptotic response of hepatocytes. Molecular and Cellular Biology. 23: 3052-66. PMID 12697808 DOI: 10.1128/MCB.23.9.3052-3066.2003  0.72
2003 Leach JK, Qiao L, Fang Y, Han SL, Gilfor D, Fisher PB, Grant S, Hylemon PB, Peterson D, Dent P. Regulation of p21 and p27 expression by the hepatitis B virus X protein and the alternate initiation site X proteins, AUG2 and AUG3. Journal of Gastroenterology and Hepatology. 18: 376-85. PMID 12653885 DOI: 10.1046/j.1440-1746.2003.02990.x  0.72
2003 Dent P, Yacoub A, Contessa J, Caron R, Amorino G, Valerie K, Hagan MP, Grant S, Schmidt-Ullrich R. Stress and radiation-induced activation of multiple intracellular signaling pathways. Radiation Research. 159: 283-300. PMID 12600231 DOI: 10.1667/0033-7587(2003)159[0283:SARIAO]2.0.CO;2  0.72
2003 Wang S, Wang Z, Dent P, Grant S. Induction of tumor necrosis factor by bryostatin 1 is involved in synergistic interactions with paclitaxel in human myeloid leukemia cells. Blood. 101: 3648-57. PMID 12522001 DOI: 10.1182/blood-2002-09-2739  0.72
2003 Wang S, Wang Z, Grant S. Bryostatin 1 and UCN-01 potentiate 1-beta-D-arabinofuranosylcytosine-induced apoptosis in human myeloid leukemia cells through disparate mechanisms. Molecular Pharmacology. 63: 232-42. PMID 12488556  0.88
2002 Yu C, Dai Y, Dent P, Grant S. Coadministration of UCN-01 with MEK1/2 inhibitors potently induces apoptosis in BCR/ABL+ leukemia cells sensitive and resistant to STI571 Cancer Biology and Therapy. 1: 674-682. PMID 12642693 DOI: 10.4161/cbt.319  0.72
2002 Grant S, Dent P. Conversion of drug-induced differentiation to apoptosis by pharmacologic cyclin-dependent kinase inhibitors Cell Cycle (Georgetown, Tex.). 1: 383-388. PMID 12548009 DOI: 10.4161/cc.1.6.260  0.72
2002 Grant S, Fisher PB, Dent P. The role of signal transduction pathways in drug and radiation resistance Cancer Treatment and Research. 112: 89-108. PMID 12481713 DOI: 10.1007/978-1-4615-1173-1_5  0.72
2002 McKinstry R, Qiao L, Yacoub A, Dai Y, Decker R, Holt S, Hagan MP, Grant S, Dent P. Inhibitors of MEK1/2 interact with UCN-01 to induce apoptosis and reduce colony formation in mammary and prostate carcinoma cells. Cancer Biology & Therapy. 1: 243-53. PMID 12432271 DOI: 10.4161/cbt.75  0.72
2002 Dai Y, Landowski TH, Rosen ST, Dent P, Grant S. Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6-independent mechanism. Blood. 100: 3333-43. PMID 12384435 DOI: 10.1182/blood-2002-03-0940  0.72
2002 Qiao L, Yacoub A, McKinstry R, Park JS, Caron R, Fisher PB, Hagan MP, Grant S, Dent P. Pharmocologic inhibitors of the mitogen activated protein kinase cascade have the potential to interact with ionizing radiation exposure to induce cell death in carcinoma cells by multiple mechanisms. Cancer Biology & Therapy. 1: 168-76. PMID 12170777 DOI: 10.4161/cbt.64  0.56
2002 Decker RH, Wang S, Dai Y, Dent P, Grant S. Loss of the Bcl-2 phosphorylation loop domain is required to protect human myeloid leukemia cells from flavopiridol-mediated mitochondrial damage and apoptosis. Cancer Biology & Therapy. 1: 136-44. PMID 12170773  0.72
2002 Qiao L, McKinstry R, Gupta S, Gilfor D, Windle JJ, Hylemon PB, Grant S, Fisher PB, Dent P. Cyclin kinase inhibitor p21 potentiates bile acid-induced apoptosis in hepatocytes that is dependent on p53. Hepatology (Baltimore, Md.). 36: 39-48. PMID 12085347 DOI: 10.1053/jhep.2002.33899  0.72
2002 Rahmani M, Dai Y, Grant S. The histone deacetylase inhibitor sodium butyrate interacts synergistically with phorbol myristate acetate (PMA) to induce mitochondrial damage and apoptosis in human myeloid leukemia cells through a tumor necrosis factor-α-mediated process Experimental Cell Research. 277: 31-47. PMID 12061815 DOI: 10.1006/excr.2002.5548  0.72
2002 Wang Z, Wang S, Dai Y, Grant S. Bryostatin 1 increases 1-beta-D-arabinofuranosylcytosine-induced cytochrome c release and apoptosis in human leukemia cells ectopically expressing Bcl-x(L). The Journal of Pharmacology and Experimental Therapeutics. 301: 568-77. PMID 11961058  0.88
2002 Qiao L, Yacoub A, Studer E, Gupta S, Pei XY, Grant S, Hylemon PB, Dent P. Inhibition of the MAPK and PI3K pathways enhances UDCA-induced apoptosis in primary rodent hepatocytes. Hepatology (Baltimore, Md.). 35: 779-89. PMID 11915023 DOI: 10.1053/jhep.2002.32533  0.72
2002 Grant S, Qiao L, Dent P. Roles of ERBB family receptor tyrosine kinases, and downstream signaling pathways, in the control of cell growth and survival Frontiers in Bioscience : a Journal and Virtual Library. 7. PMID 11815285 DOI: 10.2741/grant  0.72
2001 Qiao L, Leach K, McKinstry R, Gilfor D, Yacoub A, Park JS, Grant S, Hylemon PB, Fisher PB, Dent P. Hepatitis B virus X protein increases expression of p21Cip-1/WAF1/MDA6 and p27Kip-1 in primary mouse hepatocytes, leading to reduced cell cycle progression Hepatology. 34: 906-917. PMID 11679961 DOI: 10.1053/jhep.2001.28886  0.72
2001 Rabah D, Grant S, Ma C, Conrad DH. Bryostatin-1 specifically inhibits in vitro IgE synthesis Journal of Immunology. 167: 4910-4918. PMID 11673496 DOI: 10.4049/jimmunol.167.9.4910  0.72
2001 Leszczyniecka M, Roberts T, Dent P, Grant S, Fisher PB. Differentiation therapy of human cancer: basic science and clinical applications. Pharmacology & Therapeutics. 90: 105-56. PMID 11578655 DOI: 10.1016/S0163-7258(01)00132-2  0.72
2001 Qiao L, Studer E, Leach K, McKinstry R, Gupta S, Decker R, Kukreja R, Valerie K, Nagarkatti P, El Deiry W, Molkentin J, Schmidt-Ullrich R, Fisher PB, Grant S, Hylemon PB, et al. Deoxycholic acid (DCA) causes ligand-independent activation of epidermal growth factor receptor (EGFR) and FAS receptor in primary hepatocytes: Inhibition of EGFR/mitogen-activated protein kinase-signaling module enhances DCA-induced apoptosis Molecular Biology of the Cell. 12: 2629-2645. PMID 11553704 DOI: 10.1091/mbc.12.9.2629  0.72
2001 Yu C, Wang Z, Dent P, Grant S. MEK1/2 inhibitors promote ara-C-induced apoptosis but not loss of δψm HL-60 cells Biochemical and Biophysical Research Communications. 286: 1011-1018. PMID 11527401 DOI: 10.1006/bbrc.2001.5513  0.72
2001 Decker RH, Dai Y, Grant S. The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in human leukemia cells (U937) through the mitochondrial rather than the receptor-mediated pathway. Cell Death and Differentiation. 8: 715-24. PMID 11464216 DOI: 10.1038/sj.cdd.4400868  0.72
2001 Park JS, Qiao L, Su ZZ, Hinman D, Willoughby K, McKinstry R, Yacoub A, Duigou GJ, Young CS, Grant S, Hagan MP, Ellis E, Fisher PB, Dent P. Ionizing radiation modulates vascular endothelial growth factor (VEGF) expression through multiple mitogen activated protein kinase dependent pathways. Oncogene. 20: 3266-80. PMID 11423976 DOI: 10.1038/sj.onc.1204258  0.72
2001 Yu C, Wang S, Dent P, Grant S. Sequence-dependent potentiation of paclitaxel-mediated apoptosis in human leukemia cells by inhibitors of the mitogen-activated protein kinase kinase/mitogen-activated protein kinase pathway. Molecular Pharmacology. 60: 143-54. PMID 11408609  0.72
2001 Cartee L, Wang Z, Decker RH, Chellappan SP, Fusaro G, Hirsch KG, Sankala HM, Dent P, Grant S. The cyclin-dependent kinase inhibitor (CDKI) flavopiridol disrupts phorbol 12-myristate 13-acetate-induced differentiation and CDKI expression while enhancing apoptosis in human myeloid leukemia cells. Cancer Research. 61: 2583-91. PMID 11289135  0.72
2000 Cartee L, Davis C, Lin PS, Grant S. Chronic exposure to bryostatin-1 increases the radiosensitivity of U937 leukaemia cells ectopically expressing Bcl-2 through a non-apoptotic mechanism International Journal of Radiation Biology. 76: 1323-1333. PMID 11057740 DOI: 10.1080/09553000050151592  0.72
2000 Tang L, Boise LH, Dent P, Grant S. Potentiation of 1-β-D-arabinofuranosylcytosine-mediated mitochondrial damage and apoptosis in human leukemia cells (U937) overexpressing Bcl-2 by the kinase inhibitor 7-hydroxystaurosporine (UCN-01) Biochemical Pharmacology. 60: 1445-1456. PMID 11020446 DOI: 10.1016/S0006-2952(00)00463-9  0.72
2000 Wang Z, Wang S, Fisher PB, Dent P, Grant S. Evidence of a functional role for the cyclin-dependent kinase inhibitor p21CIP1 in leukemic cell (U937) differentiation induced by low concentrations of 1-beta-D-arabinofuranosylcytosine. Differentiation; Research in Biological Diversity. 66: 1-13. PMID 10997587 DOI: 10.1046/j.1432-0436.2000.066001001.x  0.72
1999 Vrana JA, Decker RH, Johnson CR, Wang Z, Jarvis WD, Richon VM, Ehinger M, Fisher PB, Grant S. Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53. Oncogene. 18: 7016-25. PMID 10597302 DOI: 10.1038/sj.onc.1203176  0.72
1999 Tombes RM, Mikkelsen RB, Jarvis WD, Grant S. Downregulation of δ CaM kinase II in human tumor cells Biochimica Et Biophysica Acta - Molecular Cell Research. 1452: 1-11. PMID 10525155 DOI: 10.1016/S0167-4889(99)00113-5  0.72
1999 Wang S, Wang Z, Boise LH, Dent P, Grant S. Bryostatin 1 enhances paclitaxel-induced mitochondrial dysfunction and apoptosis in human leukemia cells (U937) ectopically expressing Bcl-xL. Leukemia. 13: 1564-73. PMID 10516758  0.88
1999 Vrana JA, Kramer LB, Saunders AM, Zhang XF, Dent P, Povirk LF, Grant S. Inhibition of protein kinase C activator-mediated induction of p21CIP1 and p27KIP1 by deoxycytidine analogs in human leukemia cells: relationship to apoptosis and differentiation. Biochemical Pharmacology. 58: 121-31. PMID 10403525 DOI: 10.1016/S0006-2952(99)00077-5  0.72
1999 Vrana JA, Wang Z, Rao AS, Tang L, Chen JH, Kramer LB, Grant S. Induction of apoptosis and differentiation by fludarabine in human leukemia cells (U937): interactions with the macrocyclic lactone bryostatin 1. Leukemia. 13: 1046-55. PMID 10400420 DOI: 10.1038/sj.leu.2401454  0.88
1999 Wang S, Wang Z, Boise L, Dent P, Grant S. Loss of the bcl-2 phosphorylation loop domain increases resistance of human leukemia cells (U937) to paclitaxel-mediated mitochondrial dysfunction and apoptosis. Biochemical and Biophysical Research Communications. 259: 67-72. PMID 10334917 DOI: 10.1006/bbrc.1999.0669  0.88
1999 Vrana JA, Grant S, Dent P. Inhibition of the MAPK pathway abrogates BCL2-mediated survival of leukemia cells after exposure to low-dose ionizing radiation Radiation Research. 151: 559-569. PMID 10319729 DOI: 10.2307/3580032  0.72
1998 Dent P, Jarvis WD, Birrer MJ, Fisher PB, Schmidt-Ullrich RK, Grant S. The roles of signaling by the p42/p44 mitogen-activated protein (MAP) kinase pathway; A potential route to radio- and chemo-sensitization of tumor cells resulting in the induction of apoptosis and loss of clonogenicity Leukemia. 12: 1843-1850. PMID 9844914 DOI: 10.1038/sj.leu.2401222  0.72
1998 Jarvis WD, Fornari FA, Tombes RM, Erukulla RK, Bittman R, Schwartz GK, Dent P, Grant S. Evidence for involvement of mitogen-activated protein kinase, rather than stress-activated protein kinase, in potentiation of 1-β-D- arabinofuranosylcytosine-induced apoptosis by interruption of protein kinase C signaling Molecular Pharmacology. 54: 844-856. PMID 9804619 DOI: 10.1124/mol.54.5.844  0.72
1998 Wang S, Guo CY, Castillo A, Dent P, Grant S. Effect of bryostatin 1 on taxol-induced apoptosis and cytotoxicity in human leukemia cells (U937). Biochemical Pharmacology. 56: 635-44. PMID 9783732  0.88
1998 Wang Z, Su ZZ, Fisher PB, Wang S, VanTuyle G, Grant S. Evidence of a functional role for the cyclin-dependent kinase inhibitor p21(WAF1/CIP1/MDA6) in the reciprocal regulation of PKC activator-induced apoptosis and differentation in human myelomonocytic leukemia cells. Experimental Cell Research. 244: 105-16. PMID 9770354 DOI: 10.1006/excr.1998.4191  0.88
1998 Vrana JA, Saunders AM, Chellappan SP, Grant S. Divergent effects of bryostatin 1 and phorbol myristate acetate on cell cycle arrest and maturation in human myelomonocytic leukemia cells (U937). Differentiation; Research in Biological Diversity. 63: 33-42. PMID 9615391 DOI: 10.1046/j.1432-0436.1998.6310033.x  0.72
1998 Jarvis WD, Fornari FA, Auer KL, Freemerman AJ, Szabo E, Birrer MJ, Johnson CR, Barbour SE, Dent P, Grant S. Coordinate regulation of stress- and mitogen-activated protein kinases in the apoptotic actions of ceramide and sphingosine. Molecular Pharmacology. 52: 935-47. PMID 9415703 DOI: 10.1124/mol.52.6.935  0.56
1997 Wang S, Vrana JA, Bartimole TM, Freemerman AJ, Jarvis WD, Kramer LB, Krystal G, Dent P, Grant S. Agents that down-regulate or inhibit protein kinase C circumvent resistance to 1-beta-D-arabinofuranosylcytosine-induced apoptosis in human leukemia cells that overexpress Bcl-2. Molecular Pharmacology. 52: 1000-9. PMID 9396780  0.72
1997 Grant S. Ara-C: Cellular and molecular pharmacology Advances in Cancer Research. 72: 197-233. PMID 9338077  0.72
1997 Chelliah J, Freemerman AJ, Wu-Pong S, Jarvis WD, Grant S. Potentiation of ara-C-induced apoptosis by the protein kinase C activator bryostatin 1 in human leukemia cells (HL-60) involves a process dependent upon c-Myc Biochemical Pharmacology. 54: 563-573. PMID 9337072 DOI: 10.1016/S0006-2952(97)00212-8  0.72
1997 Grant S. Modulation of ara-C induced apoptosis in leukemia by the PKC activator bryostatin 1 Frontiers in Bioscience : a Journal and Virtual Library. 2. PMID 9195893  0.72
1997 Freemerman AJ, Vrana JA, Tombes RM, Jiang H, Chellappan SP, Fisher PB, Grant S. Effects of antisense p21 (WAF1/CIP1/MDA6) expression on the induction of differentiation and drug-mediated apoptosis in human myeloid leukemia cells (HL-60). Leukemia. 11: 504-13. PMID 9096690 DOI: 10.1038/sj.leu.2400625  0.72
1996 Fornari FA, Jarvis WD, Grant S, Orr MS, Randolph JK, White FKH, Gewirtz DA. Growth arrest and non-apoptotic cell death associated with the suppression of c-myc expression in MCF-7 breast tumor cells following acute exposure to doxorubicin Biochemical Pharmacology. 51: 931-940. PMID 8651943 DOI: 10.1016/0006-2952(96)00050-0  0.72
1996 Jarvis WD, Fornari FA, Traylor RS, Martin HA, Kramer LB, Erukulla RK, Bittman R, Grant S. Induction of apoptosis and potentiation of ceramide-mediated cytotoxicity by sphingoid bases in human myeloid leukemia cells. The Journal of Biological Chemistry. 271: 8275-84. PMID 8626522 DOI: 10.1074/jbc.271.14.8275  0.72
1994 David Jarvis W, Povirk LF, Turner AJ, Traylor RS, Gewirtz DA, Pettit GR, Grant S. Effects of bryostatin 1 and other pharmacological activators of protein kinase C on 1-[β-d-arabinofuranosyl]cytosine-induced apoptosis in HL-60 human promyelocytic leukemia cells Biochemical Pharmacology. 47: 839-852. PMID 8135859 DOI: 10.1016/0006-2952(94)90484-7  0.72
1994 Woods KE, Grant S, Yanovich S, Gewirtz DA. Variable effects of tamoxifen on human hematopoietic progenitor cell growth and sensitivity to doxorubicin. Cancer Chemotherapy and Pharmacology. 33: 509-14. PMID 7511065 DOI: 10.1007/BF00686510  0.72
1993 Grant S, Traylor R, Pettit GR, Lin PS. Modulation by bryostatin 1 of the in vitro radioprotective effects of the GM-CSF/IL-3 fusion protein, PIXY 321, on normal human myeloid progenitors Cytokine. 5: 490-497. PMID 8142605 DOI: 10.1016/1043-4666(93)90040-C  0.72
1990 Grant S. Biochemical modulation of cytosine arabinoside Pharmacology and Therapeutics. 48: 29-44. PMID 2274576 DOI: 10.1016/0163-7258(90)90016-U  0.72
1989 Bhalla K, Birkhofer M, Gongrong L, Grant S, MacLaughlin W, Cole J, Graham G, Volsky DJ. 2'-Deoxycytidine protects normal human bone marrow progenitor cells in vitro against the cytotoxicity of 3'-azido-3'-deoxythymidine with preservation of antiretroviral activity Blood. 74: 1923-1928. PMID 2572282  0.72
1985 Fisher PB, Grant S. Effects of interferon on differentiation of normal and tumor cells Pharmacology and Therapeutics. 27: 143-166. PMID 2412243 DOI: 10.1016/0163-7258(85)90067-1  0.72
1982 Grant S, Cadman E. Modulation of 1-β-D-Arabinofuranosylcytosine Metabolism and Cytotoxicity in L1210 Cells by Fluoropyrimidine Pretreatment Cancer Research. 42: 3550-3556. PMID 6213294  0.72
Show low-probability matches.